Everything below concerns Semax. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Seven-residue peptide |
| Molecular mass | 813.9 Da | Monoisotopic value |
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Also soluble in saline and polar solvents |
| Storage (dry) | -20 °C or lower | Desiccated, protected from light |
New Sudan (Arabic: السُّودَانُ الْجَدِيدُ, romanized: Āl-Südān(u) āl-Jadīd(u)) is a concept proposed by the Sudan People's Liberation Movement and the Sudan People's Liberation Movement–North, and its constituent paramilitary forces during the Second Sudanese Civil War. The original SPLM Manifesto outlined New Sudan as a proposed united and secular Sudanese state. The vision of 'New Sudan' was developed by John Garang, who advocated the 'New Sudan' as a democratic and pluralistic state. The 1994 National Convention of New Sudan (organized by SPLA/M) redefined 'New Sudan' as a system of governance for the regions under SPLM control. After John Garang's death in 2005 and the independence of South Sudan in 2011, and the resulting decreased ethnic plurality, the New Sudan discourse became a less prominent feature in Sudanese politics.
The 21st century saw the company return to independence when it was purchased from Diageo by a group of investment firms led by TPG Capital for US$1.5 billion in 2002. The new owners rapidly moved to revitalize and reorganize the company, culminating with the company being taken public in 2006 with a highly successful initial public offering. The firms' strategy for turning the chain around included a new advertising agency and new ad campaigns, a revamped menu strategy, a series of programs designed to revamp individual stores, a new restaurant concept called the BK Whopper Bar, and a new design format called 20/20. These changes successfully re-energized the company, leading to a score of profitable quarters. New owners failed to stop the Great Recession from weakening the company's outlook, even as competitor McDonald's grew. The falling value of Burger King eventually led to TPG and its partners divesting their interest in the chain in a US$3.26 billion sale to 3G Capital of Brazil. Analysts from financial firms UBS and Stifel Nicolaus agreed that 3G would have to invest heavily in the company to help reverse its fortunes. After the deal was completed, the company's stock was removed from the New York Stock Exchange, ending four years as a public company. The delisting of its stock was designed to help the company repair its fundamental business structures and continue working to close the gap with McDonald's without having to worry about pleasing shareholders.
== Treatment == Surgery, with as wide a margin of removal as possible, has generally been the most effective and preferred way to attack LMS. If surgical margins are narrow or not clear of tumor, however, or in some situations where tumor cells were left behind, chemotherapy or radiation has been shown to give a clear survival benefit. While LMS tends to be resistant to radiation and chemotherapy, each case is different and results can vary widely. For metastatic (widespread) disease, chemotherapy and targeted therapies are the first choices. Chemotherapy regimens include doxorubicin/ifosfamide and doxorubicin combination/gemcitabine and docetaxel/trabectedin; pazopanib is the targeted therapy used in metastatic leiomyosarcoma as second line and is well tolerated. LMS of uterine origin often responds to hormonal treatments. As of 2020, several clinical trials for uterine LMS are active.
In the cocurrent flow exchange mechanism, the two fluids flow in the same direction. As the cocurrent and countercurrent exchange mechanisms diagram showed, a cocurrent exchange system has a variable gradient over the length of the exchanger. With equal flows in the two tubes, this method of exchange is only capable of moving half of the property from one flow to the other, no matter how long the exchanger is. If each stream changes its property to be 50% closer to that of the opposite stream's inlet condition, exchange will stop when the point of equilibrium is reached, and the gradient has declined to zero. In the case of unequal flows, the equilibrium condition will occur somewhat closer to the conditions of the stream with the higher flow.
Sources: en.wikipedia.org
Caldwell Dyson was assigned for her second space flight on November 21, 2008. Her second space mission consisted of a six-month trip to the International Space Station. Caldwell Dyson successfully lifted off on April 2, 2010, from the Baikonur spaceport on board the Soyuz TMA-18 as Flight Engineer 2 with Soyuz Commander Aleksandr Skvortsov and Flight Engineer 1 Mikhail Korniyenko. Following a two-day rendezvous and docking maneuver with the ISS, she joined Expedition 23 as a flight engineer and transferred on June 2, 2010, to Expedition 24 again as a flight engineer after the departure of the Soyuz TMA-17. During the first half of her flight, Caldwell Dyson and the Expedition 23 crew were joined by the STS-131 crew from April 7 to April 17. This period was the first and only time that four women were together on board the same spacecraft: Caldwell Dyson, NASA astronauts Stephanie Wilson and Dorothy Metcalf-Lindenburger, and JAXA astronaut Naoko Yamazaki. From May 16 to May 23, the second and last Space Shuttle visiting mission for Caldwell-Dyson's flight, STS-132, joined the Expedition 23 crew for the installation of the Russian-built module Rassvet. The second half of Caldwell Dyson's mission was marked by the failure of a coolant pump at the beginning of August. Caldwell Dyson performed her first spacewalk on August 7, 2010, with NASA astronaut Douglas Wheelock. The task for this first of three contingency EVAs was to prepare the malfunctioning coolant pump for replacement on the next spacewalks; this took place on August 11, 2010, and August 16, 2010.
== Adverse effects == Increased urination is a commonly reported side effect, particularly during the initial phase following treatment initiation; this is mostly transient and tends to reduce with sustained treatment. Common side effects for antimineralocorticoid medications include nausea and vomiting, stomach cramps and diarrhoea. Clinically significant hyperkalemia is possible, and warrants serum potassium monitoring on a periodic basis. The pathophysiology of hyperkalemia is that antimineralocorticoid medications reduce potassium (K) excretion.
=== June === 1 June – Robert Anderson, cricketer (Otago, Central Districts, national team) (born 1948). 4 June Edwin Perry, politician, New Zealand First list MP (2002–2005), Masterton District Councillor (2007–2010) (born 1948). Bruce Stewart, lawyer, Rhodes Scholar (1975), King's Counsel (since 2000) (born 1953). 6 June – Marise Wipani, beauty pageant contestant, actor (Came a Hot Friday, Shortland Street, Soldier Soldier), and television presenter (Lotto) (born 1964). 7 June – David Lean, local politician, Mayor of New Plymouth (1980–1992), Taranaki Regional Councillor (since 1989) (born 1948). 8 June Anthony Reid, historian (Australian National University, UCLA, National University of Singapore) (born 1939). Stu Wilson, rugby union player (Wellington, national team) and television commentator (born 1954). 10 June – Roka Ngarimu-Cameron, tohunga raranga and traditional Māori arts academic (University of Otago) (born 1948). 12 June Maurice Gee, novelist (Under the Mountain, In My Father's Den, Plumb), Arts Foundation of New Zealand Icon (since 2003) (born 1931). Phil Silva, psychologist and paediatrician (University of Otago), founder (1972) and director (1972–1999) of the Dunedin Study (born 1940). Sir Cliff Skeggs, Hall of Fame businessman and local politician, Mayor of Dunedin (1977–1989) (born 1931). 14 June – Lorraine Barry, music manager (Dave Dobbyn, Ice-T, Spice Girls) (born c. 1958). 15 June – Barry Vercoe, computer scientist (Massachusetts Institute of Technology) and composer, inventor of Csound (1985) (born 1937).
== Purpose == The protein manufacturing cost remains high and there is a growing demand to develop cost efficient and rapid protein purification methods. Understanding the different protein purification methods and optimizing the downstream processing is critical to minimize production costs while maintaining the quality of acceptable standards of homogeneity. Protein purification is either preparative or analytical. Preparative purifications aim to produce a relatively large quantity of purified proteins for subsequent use. Examples include the preparation of commercial products such as enzymes (e.g. lactase), nutritional proteins (e.g. soy protein isolate), and certain biopharmaceuticals (e.g. insulin). Several preparative purification steps are often deployed to remove bi-products, such as host cell proteins, which pose a potential threat to the patient's health. Analytical purification produces a relatively small amount of a protein for a variety of research or analytical purposes, including identification, quantification, and studies of the protein's structure, post-translational modifications, and function. Each step of a protein purification scheme is monitored and takes into consideration purification levels and yield. A high purification level and a poor yield leaves hardly any protein with which to experiment. On the other hand, a high yield with low purification levels leaves many contaminants (proteins other than the one interest) which interfere with research purposes.
Improper disposal of the radionuclide cobalt-60, used in cobalt guns for radiotherapy, has led to serious radiation accidents, such as the Ciudad Juárez (Mexico) radiological accident in 1983/84, the Goiânia (Brazil) accident in 1987, the Samut Prakan (Thailand) nuclear accident in 2000, and the Mayapuri (India) accident in 2010. Eleven Therac-25 linear accelerators were built by the Canadian company Atomic Energy of Canada Limited (AECL) between 1982 and 1985 and installed in clinics in the United States and Canada. Software errors and a lack of quality assurance led to a serious malfunction that killed three patients and seriously injured three others between June 1985 and 1987 before appropriate countermeasures were taken. The radiation exposure in the six cases was subsequently estimated to be between 40 and 200 Gray; normal treatment is equivalent to a dose of less than 2 Gray. Around 1990, about one hundred cobalt guns were still in use in Germany. In the meantime, electron linear accelerators were introduced and the last cobalt gun was decommissioned in 2000.
Sources: en.wikipedia.org
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.
The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.
Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.